Pfizer signs strategic cooperation pact with Sinopharm
United States: Pfizer said on Thursday it has signed a strategic cooperation agreement with China's Sinopharm Group, and plans to seek approval to market 12 innovative drugs in China through 2025.
Read also: USFDA accepts Pfizer supplemental new drug applications for BRAFTOVI plus MEKTOVI
Sinopharm's president Liu Yong said during the signing event in Shanghai on Wednesday that the cooperation will involve accelerating the delivery of Pfizer's new drugs to patients, according to a statement from Pfizer.
Read also: Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data
Next Story